Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.56 |
| ▸ | NOS2 | P35228 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031200 | 0.83 | NOS3 (0.56) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL16668748 | 0.80 | CSNK1A1 (0.45) | NOS3NOS2NOS1CSNK1A1CLK4 | |
| SCHEMBL503132 | 0.79 | NOS3 (0.56) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL29505699 | 0.78 | UHRF1 (0.46) | CSNK1A1CLK4KDM4ENPC1ALDH1A1 | |
| SCHEMBL317517 | 0.78 | UHRF1 (0.46) | CSNK1A1CLK4KDM4ENPC1ALDH1A1 | |
| SCHEMBL1457800 | 0.78 | CSNK1A1 (0.44) | NOS3NOS2NOS1CSNK1A1CLK4 | |
| SCHEMBL30971228 | 0.78 | CSNK1A1 (0.44) | NOS3NOS2NOS1CSNK1A1CLK4 | |
| SCHEMBL21927619 | 0.77 | EGLN2 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3826142 | 0.75 | S1PR2 (0.37) | CSNK1A1CLK4KDM4ENPC1ALDH1A1 | |
| SCHEMBL286704 | 0.75 | S1PR2 (0.46) | CSNK1A1CLK4KDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119275352-A | Low-temperature electrolyte for lithium battery | 大连中比动力电池有限公司 | 2025-01-07 | — | — | CN | claimed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | claimed |
| US-5972975-A | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | claimed |
| WO-1996018616-A1 | SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| CN-119275352-A | Low-temperature electrolyte for lithium battery | 大连中比动力电池有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4253367-A1 | NOVEL BENZAZEPINE SPIRO DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-11304948-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| US-5972975-A | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1996018616-A1 | SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304948-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | NOS3 1383/4885NOS2 1462/4885NOS1 1581/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | NOS3 3027/4885NOS2 3214/4885NOS1 3536/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | NOS3 3027/4885NOS2 3214/4885NOS1 3536/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | NOS3 1383/4885NOS2 1462/4885NOS1 1581/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | NOS3 3027/4885NOS2 3214/4885NOS1 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.